AR091727A1 - Composicion anti-tumoral que comprende el compuesto 1-(6-{[6-(4-fluorofenil)[1,2,4]triazolo[4,3-b]piridazin-3-il]sulfanil}-1,3-benzotiazol-2-il)-3-(2-morfolin-4-iletil)urea - Google Patents

Composicion anti-tumoral que comprende el compuesto 1-(6-{[6-(4-fluorofenil)[1,2,4]triazolo[4,3-b]piridazin-3-il]sulfanil}-1,3-benzotiazol-2-il)-3-(2-morfolin-4-iletil)urea

Info

Publication number
AR091727A1
AR091727A1 ARP130102458A AR091727A1 AR 091727 A1 AR091727 A1 AR 091727A1 AR P130102458 A ARP130102458 A AR P130102458A AR 091727 A1 AR091727 A1 AR 091727A1
Authority
AR
Argentina
Prior art keywords
triazolo
urea
iletil
fluorophenil
piridazin
Prior art date
Application number
Other languages
English (en)
Inventor
Goulaouic Helene
Mathieu Amandine
Peracchia Maria
Teresa-Authelin Jean
Rene-Assadourian Sylvie
Benard Tsiala
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of AR091727A1 publication Critical patent/AR091727A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composición anti-tumoral que comprende el compuesto 1-(6-{[6-(4-fluorofenil)[1,2,4]triazolo[4,3-b]piridazin-3-il]sulfanil}-1,3-benzotiazol-2-il)-3-(2-morfolin-4-iletil)urea y una ciclodextrina y a su uso en el tratamiento del cáncer.
ARP130102458 2012-07-12 2013-07-11 Composicion anti-tumoral que comprende el compuesto 1-(6-{[6-(4-fluorofenil)[1,2,4]triazolo[4,3-b]piridazin-3-il]sulfanil}-1,3-benzotiazol-2-il)-3-(2-morfolin-4-iletil)urea AR091727A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12305840 2012-07-12

Publications (1)

Publication Number Publication Date
AR091727A1 true AR091727A1 (es) 2015-02-25

Family

ID=48782350

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130102458 AR091727A1 (es) 2012-07-12 2013-07-11 Composicion anti-tumoral que comprende el compuesto 1-(6-{[6-(4-fluorofenil)[1,2,4]triazolo[4,3-b]piridazin-3-il]sulfanil}-1,3-benzotiazol-2-il)-3-(2-morfolin-4-iletil)urea

Country Status (25)

Country Link
US (1) US20150119391A1 (es)
EP (1) EP2872119A1 (es)
JP (1) JP2015525754A (es)
KR (1) KR20150030761A (es)
CN (1) CN104470500A (es)
AR (1) AR091727A1 (es)
AU (1) AU2013288676A1 (es)
BR (1) BR112015000497A2 (es)
CA (1) CA2878500A1 (es)
CL (1) CL2015000074A1 (es)
CO (1) CO7160069A2 (es)
CR (1) CR20150005A (es)
EA (1) EA201590199A1 (es)
HK (1) HK1209642A1 (es)
IL (1) IL236662A0 (es)
IN (1) IN2015KN00075A (es)
MA (1) MA37753B1 (es)
MX (1) MX2015000532A (es)
PH (1) PH12015500060A1 (es)
SG (1) SG11201500123XA (es)
TN (1) TN2015000011A1 (es)
TW (1) TW201402121A (es)
UY (1) UY34909A (es)
WO (1) WO2014009500A1 (es)
ZA (1) ZA201500129B (es)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711643D0 (en) * 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
FR2817750B1 (fr) * 2000-12-11 2003-02-21 Sanofi Synthelabo Composition pharmaceutique de dronedarone pour administration parenterale
DK1594434T3 (da) * 2003-01-14 2017-01-02 Yeda Res & Dev Company Ltd At The Weizmann Inst Of Science Parenterale formuleringer af peptide til behandling af systemisk lupus erythematosus
PA8792501A1 (es) * 2007-08-09 2009-04-23 Sanofi Aventis Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.
TW200938544A (en) * 2008-02-28 2009-09-16 Takeda Pharmaceutical Pharmaceutical composition
CN101444510B (zh) * 2008-12-31 2011-03-09 南京卡文迪许生物工程技术有限公司 含有伏立康唑的药物制剂及其制备方法
FR2941951B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-nh-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.

Also Published As

Publication number Publication date
CR20150005A (es) 2015-04-06
EP2872119A1 (en) 2015-05-20
US20150119391A1 (en) 2015-04-30
CA2878500A1 (en) 2014-01-16
TW201402121A (zh) 2014-01-16
UY34909A (es) 2013-11-29
MA37753A3 (fr) 2018-05-31
IL236662A0 (en) 2015-02-26
EA201590199A1 (ru) 2015-05-29
SG11201500123XA (en) 2015-02-27
CO7160069A2 (es) 2015-01-15
CL2015000074A1 (es) 2015-06-12
ZA201500129B (en) 2015-12-23
AU2013288676A1 (en) 2015-02-05
IN2015KN00075A (es) 2015-07-31
MA37753A2 (fr) 2016-06-30
JP2015525754A (ja) 2015-09-07
HK1209642A1 (en) 2016-04-08
BR112015000497A2 (pt) 2017-06-27
MA37753B1 (fr) 2019-04-30
PH12015500060A1 (en) 2015-03-02
MX2015000532A (es) 2015-05-15
TN2015000011A1 (en) 2016-06-29
WO2014009500A1 (en) 2014-01-16
KR20150030761A (ko) 2015-03-20
CN104470500A (zh) 2015-03-25

Similar Documents

Publication Publication Date Title
CL2016001604A1 (es) “compuestos derivados de pirazolo[1,5-a]piridina, inhibidores de quinasas axl y c-met; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct
CY1121038T1 (el) Θεραπεια καρκινου μαστου
CL2012001405A1 (es) Compuestos derivados de espiroindolinona-pirrolidinas; proceso de obtención; composicion farmaceutica; y uso en el tratamiento o profilaxis del cancer.
NI201500067A (es) Compuestos de pirrolopirimidina como inhibidores de quinasa
PH12016500575A1 (en) Inhibitors of bruton`s tyrosine kinase
CL2015000829A1 (es) Inhibidores de histona desmetilasas
MX2017013613A (es) Neoepitodos de cancer.
CL2012000772A1 (es) Compuestos derivados de hetorociclos carboxamidicos sustituidos, antagonista ar; composición farmacéutica que los comprende; y uso en el tratamiento del cáncer de próstata.
CO7350624A2 (es) Inhibidores de la tirosina-quinasa de bruton
CL2015002472A1 (es) Como inhibidores de mutant idh-yl-oxazolidin-2-onas 3-pirimidin-4.
CL2008001540A1 (es) Compuestos derivados de pirrolopiridinas y pirazolopiridinas; composicion farmaceutica; y uso en el tratamiento del cancer.
CL2013000016A1 (es) Compuestos derivados de imidazopiridina; procedimiento de preparacion; composicion farmaceutica y su uso en el tratamiento del cancer.
PH12014501815A1 (en) Purinone compounds as kinase inhibitors
CL2013000018A1 (es) Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros.
UA108618C2 (uk) Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
CL2016001840A1 (es) Compuestos derivados de pirimidinas fusionadas como inhibidores del complejo p97; composicion farmaceutica y uso en el tratamiento del cancer.
CL2014001865A1 (es) Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer.
UY36075A (es) Derivados de tubulisina
CL2013002005A1 (es) Compuesto 8-[5-(1-hidroxi-1-metiletil)piridin-3-il]-1-[(2s)-2-metoxipropil]-3-metil-1,3-dihidro-2h-imidazo[4,5-c]quinazolin-2-ona; inhibidor pi3k y como mtor; composicion farmaceutica que lo comprende; combinacion farmceutica; y su uso en el tratamiento del cancer.
CL2008001373A1 (es) Compuestos derivados de fenilamino-benceno sustituidos; metodo de preparacion; composicion farmaceutica; kit farmceuticos; y uso de dichos compuestos en el tratamiento del cancer.
CY1116318T1 (el) Μακροκυκλικη ενωση και μεθοδοι για την παραγωγη της
MX2014006686A (es) Derivaods novedosos de pirrol.
DOP2015000298A (es) Compuestos nuevos para el tratamiento del cáncer
PH12015500399A1 (en) Azaindolines
MX2016005473A (es) Metodos y composiciones para mejorar la funcion renal.

Legal Events

Date Code Title Description
FB Suspension of granting procedure